We showed that HD-derived anti-BCMA CAR T cells specifically target multiple myeloma primary cells ex vivo demonstrating activity against primary multiple myeloma cells with a range of different genomic abnormalities. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.